Starting at $199 per month, including:
Women's Health Therapeutics
- Homepage
- Therepeutics
- Women's Health Therapeutics
Women's Health Therapeutics
LIONESS Health is a division of Lion Health specializing in female medical weight loss.
Spotlight: Wegovy® (semaglutatide) and Mounjarno® (terzepitide)
With an estimated 160 million Americans tipping the scales, clocking in as either overweight or obese, more individuals than ever before are seeking medical assistance to look and feel their very best.
Our medical weight loss services leave our clients proud to step on the scale and step up to the mirror. With comprehensive support including education on nutrition and dietary guidance, encouragement and motivation to stay the course, and personal training options, our clients are set up to succeed from day one.
Medical weight loss utilizes an expertly designed combination of prescription medications and dietary and lifestyle changes (such as exercise) in a controlled and monitored program custom-tailored to help each patient achieve a healthy body weight.
Each patient is supervised and monitored by medical professionals to ensure progress, safety and optimal results.
LION Health will assess if you are a candidate for medications such as Wegovy® (generic name: Semaglutide), or Mounjarno® (generic name: terzepitide), a drug treatment recently approved by the Food and Drug Administration (FDA) for chronic weight management, is administered via subcutaneous injection. It mimics the hormone known as glucagon-like peptide-1 (GLP-1), a substance that affects the areas of the brain that help regulate food intake and appetite.
Both are currently intended for patients with excess weight and obesity who have a BMI of 30 or higher of a BMI of 27 with an additional obesity related health problem. The medication is intended to supplement a habit of increased physical activity as well as a reduced calorie diet. Wegovy® or Mounjarno® alone are not likely to have the intended outcome of weight loss.
How Much Weight You’ll Lose
FDA approval came after a robust series of placebo-controlled trials with thousands of participants of varying ages. In one of the most successful trials, participants had an average initial body weight of 231 pounds and a BMI of 38.
People who received Wegovy lost an average of 14.9% of their initial body weight (a loss of about 33 pounds) during the 68-week trial. Those who received a placebo lost only 2.4% of their body weight